Aligos Therapeutics (ALGS) Set to Announce Quarterly Earnings on Thursday

Aligos Therapeutics (NASDAQ:ALGS) will likely be posting its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect Aligos Therapeutics to announce earnings of ($2.44) per share and revenue of $4.85 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Wednesday, November 4, 2026 at 9:30 AM ET.

Aligos Therapeutics (NASDAQ:ALGS) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($1.09) by $0.95. The business had revenue of $27.78 million for the quarter, compared to analyst estimates of $24.68 million. Aligos Therapeutics had a negative net margin of 241.01% and a negative return on equity of 160.72%. On average, analysts expect Aligos Therapeutics to post ($6.81) EPS for the current fiscal year and ($5.39) EPS for the next fiscal year.

Aligos Therapeutics Trading Up 9.1%

Shares of NASDAQ ALGS opened at $5.17 on Thursday. The stock has a market cap of $32.26 million, a price-to-earnings ratio of -0.71 and a beta of 2.36. Aligos Therapeutics has a 52 week low of $3.98 and a 52 week high of $13.69. The company’s 50-day moving average price is $5.63 and its 200 day moving average price is $6.31.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the stock. Weiss Ratings cut shares of Aligos Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, September 16th. HC Wainwright reaffirmed a “buy” rating on shares of Aligos Therapeutics in a report on Monday, August 10th. Finally, Jefferies Financial Group upgraded shares of Aligos Therapeutics to a “strong-buy” rating in a research report on Friday, September 25th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $38.50.

About Aligos Therapeutics

Aligos Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for viral infections and liver diseases. The company’s research programs are designed to address conditions with significant unmet medical needs, including chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), and selected respiratory viral infections.

Aligos’ pipeline has included investigational therapies such as ALG-000184, an oral capsid assembly modulator being developed for chronic HBV, and ALG-055009, an oral thyroid hormone receptor beta agonist under evaluation for MASH.